Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Triciribine

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Triciribine: Sponsors, patents, clinical trial progress

Triciribine is an investigational drug.

There have been 5 clinical trials for Triciribine. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Ovarian Neoplasms, and Neoplasms. The leading clinical trial sponsors are Prescient Therapeutics, Ltd., VioQuest Pharmaceuticals, and Albert Einstein College of Medicine of Yeshiva University.

There is one US patent protecting this investigational drug and seven international patents.

Recent Clinical Trials for Triciribine
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute LeukemiaPrescient Therapeutics, Ltd.Phase 1/Phase 2
PTX-200 and Carboplatin in Ovarian CancerPrescient Therapeutics, Ltd.Phase 1/Phase 2
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerNational Cancer Institute (NCI)Phase 1/Phase 2

See all Triciribine clinical trials

Clinical Trial Summary for Triciribine

Top disease conditions for Triciribine
Top clinical trial sponsors for Triciribine

See all Triciribine clinical trials

US Patents for Triciribine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Triciribine   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Triciribine   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Triciribine   Start Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.